We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
METFORMIN AND METFORMIN PLUS INSULIN COMBINATION EFFECT ON SOME APOPTOSIS FACTORS AND BIOCHEMICAL PARAMETERS IN TYPE 2 DIABETIC PATIENTS.
- Authors
Zaidan, Noor Khalid; Saifullah, Perry H.
- Abstract
This research was done to evaluatethe effects of anti-diabetic drugs (metformin and metformin plus insulin ) onapoptosis factors including : serum tumour necrosis factorsoluble Receptor 1(TNF-R1) Concentrationsand TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), Serum Small Mothers against Decapentaplegic family member1 (Smad1) as anew marker of diabetic nephropathy (DN), Fasting plasma glucose (FPG), Glycated HaemoglobinA1c (HbA1c%),insulinconcentration, insulin resistance (IR), urea and creatinine in type 2 diabetic patients. The study involved 51subjectssuffering from type 2 diabetes mellitus divided into 3 groups. The first group involves 17 patients and treated with metformin(as monotherapy),the second group involves of 17treated witha combination therapy ( metformin plus insulin), whereas the third group involves 17 healthy subjects as control group. Age,duration of disease and body mass index (BMI) have been determined. The results showed that the concentration of TNF-R1, Smad1 and Hb A1c% was higher in metformin monotherapy group when compared with metformin plus insulin therapy group and control group, while the concentration of TRAIL- R2, Insulin and IR was higher in metformin plus insulin therapy group than that in control group. Study conclude that using of metformin plus insulin as a combination therapyin T2DM patients can reduce (TNF-R1, Smad1 and HbA1c% ), thereby reducing the risk of developing complications related to kidney disease (Diabetic nephropathy), but did not reduce the level of TRAIL-R2 and IR in type 2 diabetic patients. So we recommend usingof metformin plus insulin as a combination therapy more than using of metformin as a monotherapy in the treatment of T2DM patients.
- Subjects
METFORMIN; APOPTOSIS; TYPE 2 diabetes; BODY mass index; INSULIN therapy
- Publication
Biochemical & Cellular Archives, 2020, Vol 20, Issue 1, p1653
- ISSN
0972-5075
- Publication type
Article
- DOI
10.35124/bca.2020.20.1.1653